Reportlinker Adds Brazil Generics Market Forecast to 2012

NEW YORK, March 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Brazil Generics Market Forecast to 2012

http://www.reportlinker.com/p0184081/Brazil-Generics-Market-Forecast-to-2012.html

Brazil, one of the major emerging powers of the world, is marking its presence in almost every dimension of the global economy, including the generic drugs industry. The generics industry has registered a significant growth rate over the last few years. The industry success is accredited to various factors like strong government support, high prevalence of diseases, inflow of investments and many more. Our new research report "Brazil Generics Market Forecast to 2012" says that the Brazilian generics market will continue to witness the same uptrend in next few years. It is expected that the generics market will post a CAGR of nearly 19% between 2010 and 2012.

Brazil is currently the largest market for generic drugs in Latin America. Analyzing the current market scenario and positive future growth, the country is set to join the group of the most potential generic drugs markets in the world. Our report has thoroughly examined the factors primarily responsible for growth of the generics industry.

Our research report has found that the Brazilian pharmaceutical market made an impressive progress over the past few years. Both public and private companies are pouring investments to develop new products, treatments and therapeutics. These companies have focused their strategies on research and development (R&D) to develop generic drugs for Oral contraceptive, Anti-diabetics, Cardiovascular and other therapeutics. Our report contains thorough information and rational analysis of these therapeutics segments.

Despite strong growth, several challenges still remain to be tackled. For instance - the prevalence of cheaper non-bioequivalent "similar drugs", low prescriptions from the private sector, and low penetration level in the private sector are big cause of concerns that need to be addressed. Our report gives some recommendations to deal with these challenges. Besides, the comprehensive information about competitive landscape has been provided in the report to give an idea about the key players' business profiles and operations.

Our research report gives a complete overview of legislative environment for generics drugs in the country, which will be useful for client in understanding the political and legal factors associated with the industry. The research study gives inclusive statistical and analytical review of demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains exhaustive information of opportunities in different sub-segments and demand analysis that will help clients in drawing market strategies and assesses opportunity areas in the Brazilian generics market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Overview

4. Market Drivers

4.1 Strong Investments

4.2 Government Initiatives

4.3 Patent Expiries

4.4 Ageing Population

4.5 Increasing Prescription Rates

5. Industry Performance

5.1 Market Size & Growth

5.2 Pharma Market Vs Generics

5.3 By Therapeutics

5.3.1 Antiretroviral

5.3.2 Oral Contraceptives

5.3.3 Erectile Dysfunction

5.3.4 Anti-thrombotics

5.3.5 Cardiovascular Drugs

5.3.6 Anti-diabetics

6. Regulatory Environment

7. Industry Restraints & RNCOS Recommendation

7.1 Dependence on Imported Raw Materials

7.2 Over-reliance of Domestic Generic Firms on Domestic Market

7.3 Lack of Awareness & Slow Acceptance by Physicians

7.4 Prevalence of 'Similar Drugs'

7.5 Counterfeit Drugs

8. Key Players

8.1 EMS Sigma Pharma

8.2 Medley

8.3 Eurofarma Laboratories Ltd

8.4 Ache Pharmaceutical Laboratories S/A

8.5 Ranbaxy

List of Figures:

Figure 4-1: Population Aged above 65 Years (%), 2005-2009

Figure 4-2: Share of Prescriptions for Branded & Generic Drugs in Pharmaceutical Market (2008 & 2009)

Figure 5-1: Generic Drugs Market (Billion BRL), 2008-2012

Figure 5-2: Share of Generic Drugs in Pharmaceutical Market (2009)

Figure 5-3: Generic Drugs Market (Million Units), 2007-2009

Figure 5-4: Forecast for Growth of Pharmaceutical & Generics Market (%), 2010-2012

Figure 5-5: Number of HIV Patients & HIV Patients on Anti-Retroviral Therapy ('000), 2006

Figure 5-6: Share of Key Players in Oral Contraceptives Market (2006)

Figure 5-7: Share of Key Players in Erectile Dysfunction Market (Nov 2006)

Figure 5-8: Deaths from Cardiovascular Diseases (%), 2005 & 2030

Figure 5-9: Cardiovascular Drugs Market (Million US$), 2005 & 2006

Figure 5-10: Share of Branded & Generic Drugs in Cardiovascular Drugs Market (2009)

Figure 5-11: Insulin Market (Million BRL), 2007-2009

Figure 7-1: Share of Imported & Locally Produced Raw Material for Pharmaceutical Market (2008)

List of Tables:

Table 4-1: Patent Expiry of Key Drugs

Table 5-1: Erectile Dysfunction Market (Million BRL), 2005 & 2006

Table 5-2: Forecast for Diabetic Patients in Age Group 20-79 ('000), 2010

Table 5-3: Forecast for Diabetic Patients in Age Group 20-79 ('000), 2030

Table 8-1: EMS Sigma Pharma - Strengths & Weaknesses

Table 8-2: Medley - Strengths & Weaknesses

Table 8-3: Eurofarma Laboratories Ltd - Strengths & Weaknesses

Table 8-4: Ache Pharmaceutical Laboratories S/A - Strengths & Weaknesses

Table 8-5: Ranbaxy - Strengths & Weaknesses

To order this report:

Generic Drug Industry: Brazil Generics Market Forecast to 2012

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker